If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the numbers actually say about the stock. Pfizer's recent share price reflects ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is drawing attention after recent trading left the shares at a last close of $27.37, with returns of 6.7% over the past month and 10.0% over ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than ...

Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic ...

Pfizer (NYSE:PFE) has agreed to acquire Metsera (NASDAQ:MTSR) in a deal worth $47.50 per share in cash, valuing the company at $4.9 billion upfront, with the potential for shareholders to receive up ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...